DATE: December 12, 2017
TIME: 10:00AM PT
Since their discovery, dendritic cells (DCs) have demonstrated a central role in the development of effective immune responses. Their unique ability to induce T cells responses to unknown antigens made them interesting research targets. However, DCs are not an easy cell type to study due to their low frequency in the periphery, lack of univocal lineage markers and the fact that they cannot be expanded in vitro. Artificial systems have been developed to obtain DC-like cells in numbers compatible with their study. The standard is to generate DCs from peripheral blood progenitors. This method has been instrumental in developing not only our basic understanding of these cells but also in translational aspects. Although the safety profile of DC approaches has been proven in several trials and objective responses were observed, their study has been hindered by technical difficulties, especially in clinical settings. Recently, individual DCs subtypes have been shown to respond differently to specific pathogen and tumor environments and that they may functionally complement each other to evoke an effective immune response.
The recent progress in immuno-oncology and the rapid development of new drugs, give us potential to design novel and effective combination strategies to contrast the complex tumor settings. DCs may be an invaluable part of approaches aiming at targeting several checkpoints of anti-tumoral immune responses. To facilitate translational studies with DCs we developed state of the art automated and closed processes to obtain clinical scale DCs, reagents produced under good manufacturing practice (GMP) and analysis tools. In this webinar we will illustrate the CliniMACS Prodigy LP-14 System for generation of monocyte-derived DCs and the innovative LP-BDC for isolation and activation of primary DCs to investigate their clinical potential.
The CliniMACS System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are manufactured and controlled under an ISO 13485-certified quality system. In the EU, the CliniMACS System components are available as CE-marked medical devices. In the US, the CliniMACS Prodigy LP-14 System is for research use only. CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use. CliniMACS, CliniMACS Prodigy, and MACS® are registered trademarks of Miltenyi Biotec GmbH. Copyright© 2017 Miltenyi BiotecPRO. All rights reserved.